XML 223 R140.htm IDEA: XBRL DOCUMENT v3.20.4
Provisions and other non-current liabilities (Details 4)
€ in Millions, ¥ in Millions, $ in Millions
Dec. 31, 2020
USD ($)
Dec. 31, 2020
EUR (€)
Dec. 31, 2020
JPY (¥)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Disclosure of other provisions [line items]          
Product liability contingency, loss exposure not accrued, number of cases 3,000 3,000 3,000    
Product liability, government investigations, other legal matters provisions $ 181     $ 200 $ 214
Product liability contingency, loss exposure not accrued, best estimate 500        
Italy | Lucentis [member]          
Disclosure of other provisions [line items]          
Estimated financial effect of contingent liabilities, maximum fine 1,300        
Estimated financial effect of contingent liabilities, damages claimed 330        
Italy | NAG and Novartis Pharma SpA [member] | Lucentis [member]          
Disclosure of other provisions [line items]          
Estimated financial effect of contingent liabilities 125        
Japan | Novartis Pharma K.K. [member]          
Disclosure of other provisions [line items]          
Estimated financial effect of contingent liabilities, maximum fine | ¥     ¥ 4    
US          
Disclosure of other provisions [line items]          
Amount of settlement in principle 300        
US | Sandoz [member]          
Disclosure of other provisions [line items]          
Product liability, government investigations, other legal matters provisions $ 187        
Description of nature of obligation contingent liabilities, number of states with alleged violations 54 54 54    
Amount of settlement in principle $ 195        
US | Sandoz [member] | Enoxaparin [member]          
Disclosure of other provisions [line items]          
Description of nature of obligation contingent liabilities, number of putative cases referred to court       1  
US | Sandoz [member] | Enoxaparin [member] | Tennessee class action [member]          
Disclosure of other provisions [line items]          
Amount of settlement in principle       $ 85  
US | Sandoz [member] | Taxotere [member]          
Disclosure of other provisions [line items]          
Product liability contingency, loss exposure not accrued, number of cases 3,000 3,000 3,000    
US | Sandoz [member] | Amiodarone [member]          
Disclosure of other provisions [line items]          
Product liability contingency, loss exposure not accrued, number of cases 5 5 5    
US | NPC and others [member]          
Disclosure of other provisions [line items]          
Amount of settlement in principle $ 700        
US | NPC and others [member] | Reclast/Aclasta [member]          
Disclosure of other provisions [line items]          
Product liability contingency, loss exposure not accrued, number of cases 20 20 20    
US | NPC and others [member] | Tasigna [member]          
Disclosure of other provisions [line items]          
Product liability contingency, loss exposure not accrued, number of cases 80 80 80    
FRANCE | F Hoffman La Roche AG and Roche SpA [member]          
Disclosure of other provisions [line items]          
Estimated financial effect of contingent liabilities, maximum fine $ 452 € 385